135 related articles for article (PubMed ID: 33167720)
1. Venetoclax induced complete remission in extramedullary relapse of AML co-harboring
Pan W; Zhao X; Shi W; Jiang Z; Xiao H
Leuk Lymphoma; 2020 Nov; 61(11):2756-2759. PubMed ID: 33167720
[No Abstract] [Full Text] [Related]
2. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia.
Wang S; Wu Z; Li T; Li Y; Wang W; Hao Q; Xie X; Wan D; Jiang Z; Wang C; Liu Y
Sci Rep; 2020 Jul; 10(1):12152. PubMed ID: 32699322
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
[TBL] [Abstract][Full Text] [Related]
4. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
5. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
[TBL] [Abstract][Full Text] [Related]
9. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
10. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
Joshi M; Cook J; McCullough K; Nanaa A; Gangat N; Foran JM; Murthy HS; Kharfan-Dabaja MA; Sproat L; Palmer J; Pardanani A; Tefferi A; Begna K; Elliot M; Al-Kali A; Patnaik M; Shah MV; Hogan WJ; Litzow MR; Alkhateeb HB
Blood Cancer J; 2021 Mar; 11(3):49. PubMed ID: 33664234
[No Abstract] [Full Text] [Related]
11. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Wu X; Zhang J; Chen Q; Zhou L; Li M; Qiu H; Sun A; Wu D
Br J Haematol; 2020 Jun; 189(5):e200-e204. PubMed ID: 32242923
[No Abstract] [Full Text] [Related]
12. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
[TBL] [Abstract][Full Text] [Related]
15. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
Zhu HH; Qian JJ; Sun WJ; You LS; Wang QQ; Naranmandura H; Jin J
Am J Hematol; 2020 Mar; 95(3):E55-E57. PubMed ID: 31907961
[No Abstract] [Full Text] [Related]
19. Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.
Flores-Jiménez JA; Pimentel-Morales MA; González-Ramella O; Vega-Cortés D; Zambrano-Velarde MÁ
J Adolesc Young Adult Oncol; 2019 Aug; 8(4):481-483. PubMed ID: 30835153
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Pfeiffer T; Li Y; Ashcraft E; Karol SE; Rubnitz JE; Epperly R; Madden R; Mamcarz E; Obeng E; Qudeimat A; Sharma A; Srinivasan A; Suliman A; Talleur AC; Velasquez MP; Gottschalk S; Triplett BM; Naik S
Bone Marrow Transplant; 2023 Mar; 58(3):328-331. PubMed ID: 36443431
[No Abstract] [Full Text] [Related]
[Next] [New Search]